Impact of pancreatic fat on the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis

被引:3
|
作者
Park, Chan Hyuk [1 ]
Chung, Moon Jae [2 ]
Park, Da Hae [3 ]
Min, Seonjeong [4 ]
Park, Se Woo [3 ]
机构
[1] Hanyang Univ, Coll Med, Dept Internal Med, Guri Hosp, Guri, Gyeonggi Do, South Korea
[2] Yonsei Univ, Severance Hosp, Dept Internal Med, Div Gastroenterol,Coll Med, Seoul, South Korea
[3] Hallym Univ, Coll Med, Dongtan Sacred Heart Hosp, Div Gastroenterol,Dept Internal Med, 7 Keunjaebong Gil, Hwaseong Si 18450, Gyeonggi Do, South Korea
[4] Hallym Univ, Coll Med, Dongtan Sacred Heart Hosp, Dept Radiol, Hwaseong, Gyeonggi Do, South Korea
关键词
Fatty pancreas; Pancreatitis; Endoscopic retrograde cholangiopancreatography; Computed tomography; BILE-DUCT STONES; ERCP PANCREATITIS; COMPLICATIONS; SEVERITY; EFFICACY; CT;
D O I
10.1007/s00464-022-09070-8
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and study aims Fatty pancreas is a potential risk factor for acute pancreatitis; however, whether it is also a risk factor for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) has not been evaluated. We aimed to determine the impact of fatty pancreas on the development of PEP. Methods We analyzed the data of patients who underwent abdominal computed tomography (CT) scan and sequential therapeutic endoscopic retrograde cholangiopancreatography (ERCP). Fatty change in the pancreas was evaluated based on pancreatic attenuation of unenhanced image on CT scan. The risk of fatty pancreas for the development of PEP was evaluated using a logistic regression model. Results Of a total of 858 patients included in the study, 354 (41.3%) had fatty pancreas, while 504 (58.7%) did not have fatty pancreas. PEP developed in 28 patients (7.9%) in the fatty pancreas group and in 13 patients (2.6%) in the no fatty pancreas group. Fatty pancreas was significantly associated with the development of PEP (odds ratio [OR] [95% confidence interval [CI]] 2.38 [1.16-4.87]). A history of acute pancreatitis, female sex, difficult cannulation, and endoscopic papillary balloon dilation were also risk factors for the development of PEP. The risk for moderate-to-severe PEP development tended to be higher in the fatty pancreas group than in the no fatty pancreas group (OR [95% CI] 5.61 [0.63-49.62]). Conclusions Fatty pancreas is a significant risk factor for the development of PEP. Clinicians need to be aware of the risk of fatty pancreas for the development of PEP prior to performing ERCP.
引用
收藏
页码:5734 / 5742
页数:9
相关论文
共 50 条
  • [41] No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Hirotoshi Ishiwatari
    Takahiro Urata
    Ichiro Yasuda
    Shimpei Matsusaki
    Hiroyuki Hisai
    Hiroshi Kawakami
    Michihiro Ono
    Takuji Iwashita
    Shinpei Doi
    Kazumichi Kawakubo
    Tsuyoshi Hayashi
    Tomoko Sonoda
    Naoya Sakamoto
    Junji Kato
    [J]. Digestive Diseases and Sciences, 2016, 61 : 3292 - 3301
  • [42] Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis by Pancreatic Duct Stenting: Should It Be Routine?
    Kozarek, Richard A.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (10) : 810 - 812
  • [43] Pancreatic stents to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis
    Mitsuru Sugimoto
    Tadayuki Takagi
    Rei Suzuki
    Naoki Konno
    Hiroyuki Asama
    Yuki Sato
    Hiroki Irie
    Ko Watanabe
    Jun Nakamura
    Hitomi Kikuchi
    Mika Takasumi
    Minami Hashimoto
    Takuto Hikichi
    Hiromasa Ohira
    [J]. World Journal of Meta-Analysis, 2019, (05) : 249 - 258
  • [44] preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta analysis
    Dan, Jiang
    Yu, Laiming
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 888 - 888
  • [45] Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis
    Khoshbaten, Manouchehr
    Khorram, Homayoun
    Madad, Leili
    Ardakani, Mohammad Javad Ehsani
    Farzin, Haleh
    Zali, Mohammmad Reza
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (07) : E11 - E16
  • [46] Best practices for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis
    Weissman, Simcha
    Ahmed, Mohamed
    Baniqued, Matthew R.
    Ehrlich, Dean
    Tabibian, James H.
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, 2021, 13 (06): : 161 - 169
  • [47] Pharmacological Prophylaxis for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PEP)
    Gochanour, Eric
    Abdelfatah, Mohamed M.
    Jampala, Nannaya
    Movahed, Hossein
    Ali, Eslam G.
    [J]. GASTROINTESTINAL ENDOSCOPY, 2017, 85 (05) : AB246 - AB246
  • [48] Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Medications and Techniques
    Wang, Andrew Y.
    Strand, Daniel S.
    Shami, Vanessa M.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (11) : 1521 - +
  • [49] No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Ishiwatari, Hirotoshi
    Urata, Takahiro
    Yasuda, Ichiro
    Matsusaki, Shimpei
    Hisai, Hiroyuki
    Kawakami, Hiroshi
    Ono, Michihiro
    Iwashita, Takuji
    Doi, Shinpei
    Kawakubo, Kazumichi
    Hayashi, Tsuyoshi
    Sonoda, Tomoko
    Sakamoto, Naoya
    Kato, Junji
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (11) : 3292 - 3301
  • [50] Indomethacin to Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: When and How?
    George, John
    Saluja, Ashok K.
    Barkin, Jamie S.
    [J]. GASTROENTEROLOGY, 2017, 152 (01) : 306 - 307